NewLink Genetics (NLNK) released updated results from its Phase 2 study of indoximod in combination with KEYTRUDA in patients with advanced melanoma Thursday morning. The results showed an improvement in complete response to 20% from 12%.
from RTT - Before the Bell http://ift.tt/2xbfOIj
via IFTTT
No comments:
Post a Comment